Video

Will The Pathway Approach Create More Efficient Clinical Trials?

Source: Clinical Leader
21_10_CLL_JanssenWebinar_1920x1080_Clip5

Drug development continues to evolve. In the last 20 years, the industry has progressed from evidence-based drug development to more targeted precision medicines. But is the industry now ready to move into a new phase of drug development?

Our October Clinical Leader Live featured three executives from Janssen discussing their work in the immunology space and the company’s current approach to discovering new treatments. The discussion focused on why development efforts are changing, what the future holds, Janssen’s current pathway approach that has the potential to treat multiple immune-mediated diseases with one therapy, and what this approach may mean to the future of clinical trials. The discussion also covered what these advancements will mean to patients, prescribers, and approval agencies. This conversation featured Newman Yeilding, Head of Immunology Development, Terence Rooney, VP of Clinical Development – Immunology, and Lloyd Miller, VP, Immunodermatology Disease Area Leader. 

In this segment, Newman Yeilding, Terence Rooney, and Lloyd Miller discuss the pathway approach to drug development and how it may reduce the time and expense of conducting clinical trials.

VIEW THE VIDEO!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader